Tags

Type your tag names separated by a space and hit enter

Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations.
Arch Bronconeumol. 2016 Feb; 52(2):88-95.AB

Abstract

OBJECTIVE

To determine the prevalence of influenza vaccination in chronic obstructive pulmonary disease (COPD) patients, and the effectiveness of the procedure.

METHODS

Retrospective population-based cohort study. On 31 December 2011, influenza vaccination history was retrieved from 899 patients with confirmed COPD selected by simple random sampling from all COPD patients in Cantabria (northern Spain). Severe exacerbations (hospitalization due to COPD exacerbation) and overall mortality during 2012 were treated as dependent variables. Odds ratios (OR) were estimated by logistic regression, adjusting for age, sex, smoking status, severity of COPD, and frequency of exacerbations during the previous year. Prevented fraction among the exposed (PFe-adjusted) was determined as a measure of impact.

RESULTS

Overall prevalence of influenza vaccination was 62.7%, but this rate fell in patients classified as more severe according to FEV1 (52.0%). Influenza vaccination showed a statistically significant protective effect against severe exacerbations in the following year: Ora: 0.54 (95%CI: 0.35-0.84); FPe-adjusted: 0.46 (95%CI: 0.16-0.65). A non-significant protective effect for overall mortality was observed: Ora: 0.76 (95%CI: 0.41-1.40). When stratified according to COPD severity (FEV1), the protective effect against risk of hospitalization was higher in more severe COPD patients: Ora: 0.23 (95%CI: 0.11-0.48); FPe-adjusted: 0.77 (95%CI: 0.52-0.89).

CONCLUSIONS

We found that influenza vaccination has a protective effect and reduces the risk of hospitalization due to exacerbations in the following year. Despite the evidence for protection, prevalence of vaccination was not optimal, especially in more severe COPD patients.

Authors+Show Affiliations

Centro de Salud de Gama, Servicio Cántabro de Salud, Bárcena de Cicero, Cantabria, España.Servicio de Neumología, Hospital Laredo, Laredo, Cantabria, España.Centro de Salud de Liérganes, Servicio Cántabro de Salud, Miera, Cantabria, España.Centro de Salud Bajo Asón, Servicio Cántabro de Salud, Ampuero, Cantabria, España.Centro de Salud de Suances, Servicio Cántabro de Salud, Suances, Cantabria, España.Centro de Salud Campoo-Los Valles, Servicio Cántabro de Salud, Mataporquera, Cantabria, España.Centro de Salud de Suances, Servicio Cántabro de Salud, Suances, Cantabria, España.Área de Medicina Preventiva y Salud Pública, Universidad de Cantabria-IDIVAL, Santander, España.Área de Medicina Preventiva y Salud Pública, Universidad de Cantabria-IDIVAL, Santander, España. Electronic address: santibanezm@unican.es.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng spa

PubMed ID

26526292

Citation

Garrastazu, Roberto, et al. "Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact On the Risk of Severe Exacerbations." Archivos De Bronconeumologia, vol. 52, no. 2, 2016, pp. 88-95.
Garrastazu R, García-Rivero JL, Ruiz M, et al. Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations. Arch Bronconeumol. 2016;52(2):88-95.
Garrastazu, R., García-Rivero, J. L., Ruiz, M., Helguera, J. M., Arenal, S., Bonnardeux, C., León, C., Llorca, J., & Santibañez, M. (2016). Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations. Archivos De Bronconeumologia, 52(2), 88-95. https://doi.org/10.1016/j.arbres.2015.09.001
Garrastazu R, et al. Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact On the Risk of Severe Exacerbations. Arch Bronconeumol. 2016;52(2):88-95. PubMed PMID: 26526292.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Prevalence of Influenza Vaccination in Chronic Obstructive Pulmonary Disease Patients and Impact on the Risk of Severe Exacerbations. AU - Garrastazu,Roberto, AU - García-Rivero,Juan Luis, AU - Ruiz,Mario, AU - Helguera,Jose Manuel, AU - Arenal,Sandra, AU - Bonnardeux,Cristina, AU - León,Carlos, AU - Llorca,Javier, AU - Santibañez,Miguel, Y1 - 2015/10/29/ PY - 2015/05/11/received PY - 2015/09/01/revised PY - 2015/09/03/accepted PY - 2015/11/4/entrez PY - 2015/11/4/pubmed PY - 2016/11/2/medline KW - Chronic obstructive pulmonary disease KW - Enfermedad pulmonar obstructiva crónica KW - Influenza vaccines KW - Prevención primaria KW - Primary prevention KW - Vacunación antigripal SP - 88 EP - 95 JF - Archivos de bronconeumologia JO - Arch. Bronconeumol. VL - 52 IS - 2 N2 - OBJECTIVE: To determine the prevalence of influenza vaccination in chronic obstructive pulmonary disease (COPD) patients, and the effectiveness of the procedure. METHODS: Retrospective population-based cohort study. On 31 December 2011, influenza vaccination history was retrieved from 899 patients with confirmed COPD selected by simple random sampling from all COPD patients in Cantabria (northern Spain). Severe exacerbations (hospitalization due to COPD exacerbation) and overall mortality during 2012 were treated as dependent variables. Odds ratios (OR) were estimated by logistic regression, adjusting for age, sex, smoking status, severity of COPD, and frequency of exacerbations during the previous year. Prevented fraction among the exposed (PFe-adjusted) was determined as a measure of impact. RESULTS: Overall prevalence of influenza vaccination was 62.7%, but this rate fell in patients classified as more severe according to FEV1 (52.0%). Influenza vaccination showed a statistically significant protective effect against severe exacerbations in the following year: Ora: 0.54 (95%CI: 0.35-0.84); FPe-adjusted: 0.46 (95%CI: 0.16-0.65). A non-significant protective effect for overall mortality was observed: Ora: 0.76 (95%CI: 0.41-1.40). When stratified according to COPD severity (FEV1), the protective effect against risk of hospitalization was higher in more severe COPD patients: Ora: 0.23 (95%CI: 0.11-0.48); FPe-adjusted: 0.77 (95%CI: 0.52-0.89). CONCLUSIONS: We found that influenza vaccination has a protective effect and reduces the risk of hospitalization due to exacerbations in the following year. Despite the evidence for protection, prevalence of vaccination was not optimal, especially in more severe COPD patients. SN - 1579-2129 UR - https://www.unboundmedicine.com/medline/citation/26526292/Prevalence_of_Influenza_Vaccination_in_Chronic_Obstructive_Pulmonary_Disease_Patients_and_Impact_on_the_Risk_of_Severe_Exacerbations_ L2 - http://www.archbronconeumol.org/en/linksolver/ft/pii/S0300-2896(15)00354-3 DB - PRIME DP - Unbound Medicine ER -